Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty

@article{Anderson2013AspirinVL,
  title={Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty},
  author={David R Anderson and Michael Dunbar and Eric Bohm and Etienne L. Belzile and Susan R. Kahn and David J. Zukor and William Fisher and Wade T Gofton and Peter L. Gross and St{\'e}phane Pelet and Mark Andrew Crowther and Steven J MacDonald and Paul Kim and Susan Pleasance and Nicki Davis and Pantelis Andreou and Philip Stephen Wells and Michael J. Kovacs and Marc Alan Rodger and Tim Ramsay and Marc Carrier and Pascal-Andr{\'e} Vendittoli},
  journal={Annals of Internal Medicine},
  year={2013},
  volume={158},
  pages={800 - 806}
}
BACKGROUND The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based… 
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial
TLDR
The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients, and LMWH demonstrated a 60.5% VTE Prevention benefit in the weighted time to event analysis.
Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
TLDR
This article adds useful information on the role of aspirin in the orthopedic setting and the generalizability of the findings is probably questionable given the recent availability of novel oral anticoagulants for VTE prophylaxis after hip replacement.
Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
TLDR
This article adds useful information on the role of aspirin in the orthopedic setting and the generalizability of the findings is probably questionable given the recent availability of novel oral anticoagulants for VTE prophylaxis after hip replacement.
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty.
TLDR
Low-dose aspirin was not inferior to high- dose aspirin for the prevention of VTE after TKA and can be considered a safe and effective agent in the prevention in venous thromboembolism after total knee arthroplasty.
Inpatient compliance with venous thromboembolism prophylaxis after orthopaedic trauma: results from a randomized controlled trial of aspirin versus low molecular weight heparin
TLDR
These data should reassure clinicians that inpatient compliance is similar for low molecular weight heparin and aspirin regimens, as well as reassure patients that venous thromboembolism prophylaxis regimens are safe.
Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry.
TLDR
Aspirin is not inferior to other anticoagulants as pharmacologic venous thromboembolism prophylaxis with regards to post-operative risk of venous Thrombosis or bleeding and should be considered in the appropriate patient.
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
TLDR
Aspirin and factor Xa inhibitors provided improved DVT prophylaxis with lower rates of postoperative anaemia compared to enoxaparin and warfarin and the utilisation of aspirin and factorXa inhibitors increased over time.
Evaluation of Pharmacologic Strategies for Prevention of Venous Thromboembolism in Elective Orthopedic Surgery
Background: Venous thromboembolism (VTE) is a common postoperative complication in orthopedic surgery and warrants the use of pharmacologic thromboprophylaxis. The purpose of this study was to
Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis
TLDR
This study demonstrates that low-dose aspirin is not inferior to high- dose aspirin for venous thromboembolism prophylaxis following total joint arthroplasty and is associated with fewer gastrointestinal side effects.
Is Apixaban Safe and Effective for Venous Thromboembolism Prophylaxis After Primary Total Hip and Total Knee Arthroplasties?
TLDR
The use of apixaban for V TE prophylaxis after primary THA and TKA in patients at high risk for VTE, in patients previously on apixaba, and in patients with a contraindication to the use of aspirin is associated with a low risk of VTE and bleeding complications.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
TLDR
A systematic review is performed to provide clinicians with a practical pathway for translating clinical research into practice and suggest a need for extended out-of-hospital prophylaxis in patients undergoing total-hip replacement but not for patients undergoingtotal-knee replacement.
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
TLDR
There were significantly fewer venous thromboembolic complications in patients undergoing elective hip replacement when prophylaxis with enoxaparin was given for a total of one month, rather than only during the hospitalization.
Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials
TLDR
Among patients undergoing total hip or knee replacement, extended-duration prophylaxis significantly reduces the frequency of symptomatic venous thromboembolism and the reduction in risk is equivalent to about 20 symptomatic events per 1000 patients treated.
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review.
TLDR
The absolute reduction in symptomatic venous thromboembolism attributed to extended prophylaxis in some studies and meta-analyses seems to have been overestimated.
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
TLDR
It is concluded that prolonged (35 days) thrombo prophylaxis with dalteparin is more effective than a standard length regimen without increased risk of bleeding complications or other adverse events.
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
TLDR
Results show that aspirin reduces the risk of pulmonary embolism and deep-vein thrombosis by at least a third throughout a period of increased risk, and there is now good evidence for considering aspirin routinely in a wide range of surgical and medical groups at high risk of venous thromboembolism.
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
TLDR
Extended dalteparin prophylaxis resulted in significantly lower frequencies of deep vein thrombosis compared with in-hospital warfarin therapy, and will lessen the burden to both the patient and society.
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
TLDR
The results should be considered when the conflicting recommendations of existing guidelines for thromboprophylaxis after hip replacement are being addressed.
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
TLDR
Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
TLDR
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once- daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty.
...
1
2
3
4
...